565 related articles for article (PubMed ID: 32700154)
41. New Perspectives on Antimicrobial Agents: Cefiderocol.
McCreary EK; Heil EL; Tamma PD
Antimicrob Agents Chemother; 2021 Jul; 65(8):e0217120. PubMed ID: 34031052
[TBL] [Abstract][Full Text] [Related]
42. Ceftazidime-Avibactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination for the Treatment of Resistant Gram-negative Organisms.
Sharma R; Park TE; Moy S
Clin Ther; 2016 Mar; 38(3):431-44. PubMed ID: 26948862
[TBL] [Abstract][Full Text] [Related]
43. US Food and Drug Administration (FDA): Benefit-Risk Considerations for Cefiderocol (Fetroja®).
Naseer S; Weinstein EA; Rubin DB; Suvarna K; Wei X; Higgins K; Goodwin A; Jang SH; Iarikov D; Farley J; Nambiar S
Clin Infect Dis; 2021 Jun; 72(12):e1103-e1111. PubMed ID: 33393598
[TBL] [Abstract][Full Text] [Related]
44. Pharmacokinetic evaluation of cefiderocol for the treatment of multidrug resistant Gram-negative infections.
Drwiega EN; Griffith NC; Danziger LH
Expert Opin Drug Metab Toxicol; 2022 Apr; 18(4):245-259. PubMed ID: 35594628
[TBL] [Abstract][Full Text] [Related]
45. Pharmacodynamics of cefiderocol, a novel siderophore cephalosporin, in a Pseudomonas aeruginosa neutropenic murine thigh model.
Ghazi IM; Monogue ML; Tsuji M; Nicolau DP
Int J Antimicrob Agents; 2018 Feb; 51(2):206-212. PubMed ID: 29111435
[TBL] [Abstract][Full Text] [Related]
46.
Mushtaq S; Sadouki Z; Vickers A; Livermore DM; Woodford N
Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 32958717
[TBL] [Abstract][Full Text] [Related]
47. Activity of the novel siderophore cephalosporin cefiderocol against multidrug-resistant Gram-negative pathogens.
Dobias J; Dénervaud-Tendon V; Poirel L; Nordmann P
Eur J Clin Microbiol Infect Dis; 2017 Dec; 36(12):2319-2327. PubMed ID: 28748397
[TBL] [Abstract][Full Text] [Related]
48. Investigator-Driven Randomised Controlled Trial of Cefiderocol versus Standard Therapy for Healthcare-Associated and Hospital-Acquired Gram-negative Bloodstream Infection: Study protocol (the GAME CHANGER trial): study protocol for an open-label, randomised controlled trial.
Wright H; Harris PNA; Chatfield MD; Lye D; Henderson A; Harris-Brown T; Donaldson A; Paterson DL
Trials; 2021 Dec; 22(1):889. PubMed ID: 34876196
[TBL] [Abstract][Full Text] [Related]
49. Activity of Cefiderocol and Comparators against Isolates from Cancer Patients.
Rolston KVI; Gerges B; Shelburne S; Aitken SL; Raad I; Prince RA
Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32071053
[TBL] [Abstract][Full Text] [Related]
50. Cefiderocol to treat complicated urinary tract infection.
McCarthy MW
Drugs Today (Barc); 2020 Mar; 56(3):177-184. PubMed ID: 32282864
[TBL] [Abstract][Full Text] [Related]
51. [Post-marketing surveillance of antibacterial activities of cefozopran against various clinical isolates--II. Gram-negative bacteria].
Igari J; Oguri T; Hiramatsu N; Akiyama K; Koyama T
Jpn J Antibiot; 2002 Feb; 55(1):22-60. PubMed ID: 11977920
[TBL] [Abstract][Full Text] [Related]
52. Mechanisms of Reduced Susceptibility to Cefiderocol Among Isolates from the CREDIBLE-CR and APEKS-NP Clinical Trials.
Nordmann P; Shields RK; Doi Y; Takemura M; Echols R; Matsunaga Y; Yamano Y
Microb Drug Resist; 2022 Apr; 28(4):398-407. PubMed ID: 35076335
[TBL] [Abstract][Full Text] [Related]
53. In vitro activity of cefiderocol and other newly approved antimicrobials against multi-drug resistant Gram-negative pathogens recovered in intensive care units in Spain and Portugal.
Gijón D; García-Castillo J; Fernández-López MC; Bou G; Siller M; Calvo-Montes J; Pitart C; Vila J; Torno N; Gimeno C; Cruz H; Ramos H; Mulet X; Oliver A; Ruiz-Garbajosa P; Canton R
Rev Esp Quimioter; 2024 Feb; 37(1):69-77. PubMed ID: 37882320
[TBL] [Abstract][Full Text] [Related]
54. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.
Zhanel GG; Lawrence CK; Adam H; Schweizer F; Zelenitsky S; Zhanel M; Lagacé-Wiens PRS; Walkty A; Denisuik A; Golden A; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
Drugs; 2018 Jan; 78(1):65-98. PubMed ID: 29230684
[TBL] [Abstract][Full Text] [Related]
55. Cefiderocol: Discovery, Chemistry, and In Vivo Profiles of a Novel Siderophore Cephalosporin.
Sato T; Yamawaki K
Clin Infect Dis; 2019 Nov; 69(Suppl 7):S538-S543. PubMed ID: 31724047
[TBL] [Abstract][Full Text] [Related]
56. Cefiderocol for the Treatment of Infections Due to Metallo-B-lactamase-Producing Pathogens in the CREDIBLE-CR and APEKS-NP Phase 3 Randomized Studies.
Timsit JF; Paul M; Shields RK; Echols R; Baba T; Yamano Y; Portsmouth S
Clin Infect Dis; 2022 Sep; 75(6):1081-1084. PubMed ID: 35148378
[TBL] [Abstract][Full Text] [Related]
57. [Discovery of a New Siderophore Cephalosporin, Cefiderocol].
Yamano Y
Yakugaku Zasshi; 2024; 144(6):627-631. PubMed ID: 38825471
[TBL] [Abstract][Full Text] [Related]
58. Burkholderia pseudomallei Clinical Isolates Are Highly Susceptible
Burnard D; Robertson G; Henderson A; Falconer C; Bauer MJ; Cottrell K; Gassiep I; Norton R; Paterson DL; Harris PNA
Antimicrob Agents Chemother; 2021 Jan; 65(2):. PubMed ID: 33168603
[TBL] [Abstract][Full Text] [Related]
59. Cefiderocol: a novel siderophore cephalosporin.
Choi JJ; McCarthy MW
Expert Opin Investig Drugs; 2018 Feb; 27(2):193-197. PubMed ID: 29318906
[TBL] [Abstract][Full Text] [Related]
60. Real-life use of cefiderocol for salvage therapy of severe infections due to carbapenem-resistant Gram-negative bacteria.
de la Fuente C; Rodríguez M; Merino N; Carmona P; Machuca I; Córdoba-Fernández M; Guzmán-Puche J; Domínguez A; López-Viñau T; García L; Vaquero JM; Robles JC; Martínez-Martínez L; Torre-Cisneros J
Int J Antimicrob Agents; 2023 Jul; 62(1):106818. PubMed ID: 37062445
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
